US equities
|
MU
$1,040.53
▼-4.36%
NVDA
$230.38
▼-2.99%
SNDK
$1,609.28
▼-4.91%
AMD
$618.34
▼-4.26%
INTC
$105.89
▼-6.39%
SPCX
$162.16
▼-3.25%
META
$716.46
▼-0.67%
PLTR
$196.26
▲+1.10%
MU
$1,040.53
▼-4.36%
NVDA
$230.38
▼-2.99%
SNDK
$1,609.28
▼-4.91%
AMD
$618.34
▼-4.26%
INTC
$105.89
▼-6.39%
SPCX
$162.16
▼-3.25%
META
$716.46
▼-0.67%
PLTR
$196.26
▲+1.10%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
17.93
+0.43 (+2.43%)
Delayed Quote
Updated: 1:59 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
36
37
Next >
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
May 22, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
May 21, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Assessing Sarepta Therapeutics: Insights From 30 Financial Analysts
↗
May 20, 2025
Via
Benzinga
SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays
May 19, 2025
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 80.2% year on year to $744.9 million. Its non-GAAP loss of $3.42...
Via
StockStory
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
May 16, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
May 16, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
2 Healthcare Stocks to Keep an Eye On and 1 to Ignore
May 15, 2025
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of...
Via
StockStory
Topics
Stocks
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
May 14, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
May 14, 2025
Via
TheNewswire.com
Topics
Fraud
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
May 14, 2025
These 3 pharma stocks have oversold RSIs and solid analyst support, setting up potential bounce-back trades through this week and next
Via
MarketBeat
Topics
Earnings
Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%
↗
May 13, 2025
Roche's APHINITY study shows promising results for HER2-positive breast cancer treatment with Perjeta regime
Via
Benzinga
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
May 13, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying
↗
May 13, 2025
Via
The Motley Fool
Topics
Cannabis
Law Enforcement
Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets
↗
May 10, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
May 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
May 09, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
May 09, 2025
RADNOR, PA - May 9, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of...
Via
TheNewswire.com
Topics
Fraud
Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
↗
May 09, 2025
Via
Benzinga
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
May 08, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
May 08, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
May 08, 2025
RADNOR, PA - May 8, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of...
Via
TheNewswire.com
Topics
Fraud
Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
May 07, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta...
Via
StockStory
Topics
Artificial Intelligence
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
May 07, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
May 07, 2025
RADNOR, PA - May 7, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of...
Via
TheNewswire.com
Topics
Fraud
Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why
May 07, 2025
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 20.5% in the afternoon session after the company reported weak first quarter 2025 results which featured drastically lowered full-year...
Via
StockStory
Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up
↗
May 07, 2025
Sarepta posted a deeper-than-expected Q1 loss and cut its 2025 forecast due to Elevidys rollout delays, despite beating revenue estimates.
Via
Benzinga
The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low
↗
May 07, 2025
Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA appointment.
Via
Investor's Business Daily
Topics
Death
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
↗
May 07, 2025
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.
Via
Benzinga
Sarepta Therapeutics Analysts Slash Their Forecasts After Q1 Results
↗
May 07, 2025
Via
Benzinga
Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
May 07, 2025
Via
Benzinga
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
36
37
Next >
